All Episodes – Page 2

“Molecular Glue Degrader Improves Outcomes in Heavily Pre-treated Patients with Advanced Solid Tumors” An interview with: Elena Garralda MD PhD, Medical Oncologist, Head, Early Drug Development Unit,

Safe to Avoid Endocrine Therapy in Older Women with Low Risk Breast Cancers: EUROPA Study Interim Findings An interview with: Icro Meattini MD, Associate Professor of Radiotherapy, University of Flore

Axillary Radiotherapy Seems As Effective as Axillary Lymphadenectomy in Sentinel Node Positive Early Breast Cancer, with Less Risk of Lymphedema An interview with: Amparo Garcia-Tejedor MD, PhD, Profe

Radiation Boost May No Longer Be Justified After Standard Therapy for Early Breast Cancer An interview with: Eline Verreck BSc, Erasmus University Medical Centre, Surgical Oncology Department, Rotterd

Fleur Mauritz MD discusses the 10-year follow-up findings from the RAPCHEM study, presented at the EBCC 2026. The research indicates that risk-based radiotherapy de-escalation is safe and effective following primary systemic therapy for early breast cancer patients. This approach allows for tailored treatment, potentially reducing side effects without compromising low recurrence rates. The study provides crucial long-term evidence supporting individualized radiotherapy strategies.

At the 2026 EBCC, Jelle Wesseling MD PhD discusses the LORD-trial, which found active surveillance for low-risk, estrogen-receptor-positive, HER2-negative, grade 1–2 DCIS is as effective as standard therapy. The trial's reassuring findings led to early cessation of randomization, supporting de-escal

Elisa Agostinetto MD presented at EBCC 2026, highlighting circulating tumor DNA (ctDNA) as a superior prognostic marker over clinical indicators for predicting relapse and progression in early breast cancer patients after neoadjuvant therapy. This research supports ctDNA for post-neoadjuvant risk st

Kerstin Wimmer MD, at the 2026 EBCC, discussed the OPBC-09 PRExRT study findings, revealing that polyurethane-coated breast implants significantly reduce capsular contracture risk for breast cancer patients receiving mastectomy with immediate pre-pectoral reconstruction followed by radiotherapy. Thi

At EBCC 2026, Fatima Cardoso MD discussed the OASIS-4 trial, revealing elinzanetant greatly reduced vasomotor symptoms ("hot flashes") in breast cancer patients receiving endocrine therapy. This dual neurokinin receptor antagonist demonstrated rapid and sustained efficacy across various ET types, of

Elisabetta Bonzano MD PhD discusses the BRAVE-HEART study at the 2025 EBCC, revealing how the Active Breathing Co-ordination (ABC) system significantly halves the coronary radiation dose during left breast irradiation. This crucial finding confirms ABC's high feasibility and clinical impact in reduc

This episode features Philip Poortmans MD PhD, University of Antwerp & Iridium Netwerk, discussing key themes from the 2026 European Breast Cancer Conference. He focuses on individualizing breast cancer therapy through de-escalation, covering the EUROPA trial, radiation boost data, axillary radiothe

Tess Snellen MD, from the Netherlands Cancer Institute, presents key findings at the EBCC 2026 regarding a molecular test. This innovative test utilizes next-generation sequencing to precisely differentiate between a recurrent ipsilateral breast cancer and a new primary tumor, significantly aiding i

Charles E Geyer MD, at ESMO 2025, discusses DESTINY-Breast05 results, revealing trastuzumab deruxtecan (T-DXd) significantly improves disease-free survival for HER2-positive early breast cancer patients with residual invasive disease after neoadjuvant therapy. T-DXd outperformed trastuzumab emtansin

Hope S. Rugo, MD, discusses the Phase III evERA Breast Cancer trial at SABCS 2025, revealing clinically meaningful improvements with giredestrant plus everolimus for ER-positive, HER2-negative metastatic breast cancer previously treated with a CDK4/6 inhibitor. Subgroup analyses show benefits regard

Othman Al-Sawaf MD PhD, a hematologist from University Hospital of Cologne, presents early data from the CLL17 international phase three trial at ASH 2025. The findings indicate that fixed-duration treatment with venetoclax plus obinutuzumab or venetoclax plus ibrutinib is non-inferior to continuous ibrutinib for patients with previously untreated chronic lymphocytic leukemia, potentially becoming the preferred treatment.

Dr. Juan Du presented early phase one study findings at ASH 2025, detailing a novel dual-targeted FasTCAR-T therapy for newly diagnosed multiple myeloma. The study demonstrated deep, durable responses in patients using the BCMA and CD19-targeting CAR T-cell platform, GC012F/AZD0120. These promising results, consistent across all dose groups, highlight a highly favorable safety profile and potential for patients, including those with high-risk features and transplant-ineligible individuals.

Thorsten Kühn MD PhD discusses findings from the AXSANA/EUBREAST 3(R) study at SABCS 2025. The research indicates that breast cancer patients who convert from clinically node-positive to node-negative after neoadjuvant chemotherapy do not require axillary lymph node dissection. Less invasive surgical staging procedures were found to be non-inferior in terms of three-year outcomes, irrespective of tumor type or initial stage.

This podcast episode, recorded at ASH 2025, features an interview with María-Victoria Mateos MD PhD, who discusses groundbreaking findings from the Majestec-3 study. The study highlights unprecedented survival benefits with the BCMA/CD3 bispecific antibody teclistamab. In patients with relapsed or refractory multiple myeloma, adding teclistamab to standard second-line therapies significantly improved progression-free and overall survival.

This episode features an interview with Erika Hamilton MD at the 2025 San Antonio Breast Cancer Symposium (SABCS). Dr. Hamilton discusses findings from the HER2CLIMB-05 trial, showing that adding tucatinib to trastuzumab and pertuzumab significantly improves progression-free survival in patients with HER2-positive metastatic breast cancer as first-line maintenance therapy, with no new safety signals. This small molecule HER2 inhibitor offers a promising new option.

Wojciech Jurczak MD PhD discusses research from ASH 2025, revealing that the non-covalent BTK inhibitor pirtobrutinib is superior to bendamustine plus rituximab as initial therapy for untreated chronic lymphocytic leukemia and small lymphocytic lymphoma. The BRUIN CLL-313 phase 3 study found pirtobrutinib significantly improved progression-free survival and was well-tolerated. These data suggest pirtobrutinib could become a new standard of care for these patients.